Jennifer Buell
CIK: 0001711184
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (20 total)
- Oct 12, 2026INKT
MiNK Therapeutics, Inc.
Sale(S)Direct6.9K shares at avg. $10.56$73K - Oct 11, 2026INKT
MiNK Therapeutics, Inc.
Exercise(M)Direct23.2K shares- - Aug 5, 2026AGEN
AGENUS INC
Award(A)DirectStock Option
200K shares- - Apr 24, 2026AGEN
AGENUS INC
Award(A)DirectStock Option
5K shares- - Apr 24, 2026AGEN
AGENUS INC
Award(A)DirectStock Option
300K shares- - Jan 2, 2026INKT
MiNK Therapeutics, Inc.
Tax Payment(F)Direct10K shares at avg. $11.12$111K - Jan 2, 2026INKT
MiNK Therapeutics, Inc.
Award(A)Direct31.5K shares at avg. $11.12$350K - Sep 9, 2025INKT
MiNK Therapeutics, Inc.
Tax Payment(F)Direct5.4K shares at avg. $15.36$82K - Sep 9, 2025INKT
MiNK Therapeutics, Inc.
Award(A)Direct18.2K shares at avg. $15.36$280K - May 2, 2025AGEN
AGENUS INC
Award(A)Direct581 shares at avg. $3.11$2K - Apr 18, 2025AGEN
AGENUS INC
Award(A)Direct869 shares at avg. $2.08$2K - Apr 4, 2025AGEN
AGENUS INC
Award(A)Direct1.2K shares at avg. $1.56$2K - Mar 21, 2025AGEN
AGENUS INC
Award(A)Direct1.1K shares at avg. $1.61$2K - Mar 7, 2025AGEN
AGENUS INC
Award(A)Direct409 shares at avg. $2.35$961.15 - Feb 21, 2025AGEN
AGENUS INC
Award(A)Direct545 shares at avg. $3.32$2K - Feb 21, 2025AGEN
AGENUS INC
Award(A)Direct626 shares at avg. $3.32$2K - Feb 7, 2025AGEN
AGENUS INC
Award(A)Direct516 shares at avg. $3.50$2K - Jan 24, 2025AGEN
AGENUS INC
Tax Payment(F)Direct270 shares at avg. $3.57$963.9 - Jan 24, 2025AGEN
AGENUS INC
Award(A)Direct776 shares at avg. $3.57$3K - Nov 14, 2024AGEN
AGENUS INC
Award(A)DirectStock Option
300K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 12, 2026 |  INKT MiNK Therapeutics, Inc. | Sale(S) | 6,938 | $10.56 | $73,265 | Direct |
| Oct 11, 2026 | INKT MiNK Therapeutics, Inc. | Exercise(M) | 23,191 | - | $0 | Direct |
| Aug 5, 2026 |  AGEN AGENUS INC | Award(A) Stock Option | 200,000 | - | - | Direct |
| Apr 24, 2026 | AGEN AGENUS INC | Award(A) Stock Option | 5,000 | - | - | Direct |
| Apr 24, 2026 | AGEN AGENUS INC | Award(A) Stock Option | 300,000 | - | - | Direct |
| Jan 2, 2026 | INKT MiNK Therapeutics, Inc. | Tax Payment(F) | 10,024 | $11.12 | $111,467 | Direct |
| Jan 2, 2026 | INKT MiNK Therapeutics, Inc. | Award(A) | 31,474 | $11.12 | $349,991 | Direct |
| Sep 9, 2025 | INKT MiNK Therapeutics, Inc. | Tax Payment(F) | 5,351 | $15.36 | $82,191 | Direct |
| Sep 9, 2025 | INKT MiNK Therapeutics, Inc. | Award(A) | 18,229 | $15.36 | $279,997 | Direct |
| May 2, 2025 | AGEN AGENUS INC | Award(A) | 581 | $3.11 | $1,807 | Direct |
| Apr 18, 2025 | AGEN AGENUS INC | Award(A) | 869 | $2.08 | $1,808 | Direct |
| Apr 4, 2025 | AGEN AGENUS INC | Award(A) | 1,159 | $1.56 | $1,808 | Direct |
| Mar 21, 2025 | AGEN AGENUS INC | Award(A) | 1,123 | $1.61 | $1,808 | Direct |
| Mar 7, 2025 | AGEN AGENUS INC | Award(A) | 409 | $2.35 | $961 | Direct |
| Feb 21, 2025 | AGEN AGENUS INC | Award(A) | 545 | $3.32 | $1,809 | Direct |
| Feb 21, 2025 | AGEN AGENUS INC | Award(A) | 626 | $3.32 | $2,078 | Direct |
| Feb 7, 2025 | AGEN AGENUS INC | Award(A) | 516 | $3.50 | $1,806 | Direct |
| Jan 24, 2025 | AGEN AGENUS INC | Tax Payment(F) | 270 | $3.57 | $964 | Direct |
| Jan 24, 2025 | AGEN AGENUS INC | Award(A) | 776 | $3.57 | $2,770 | Direct |
| Nov 14, 2024 | AGEN AGENUS INC | Award(A) Stock Option | 300,000 | - | - | Direct |
1-20 of 20 transactions
About Buell Jennifer
Buell Jennifer (SEC CIK 0001711184) files insider reports with the SEC as Chief Executive Officer of MiNK Therapeutics, Inc. (INKT) and Director of AGENUS INC (AGEN).
Signal8 holds 18 ownership filings by Buell Jennifer, all Form 4s, filed between Nov 18, 2024 and Oct 14, 2026. Those filings report 20 transactions, from Nov 14, 2024 to Oct 12, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Buell Jennifer's filings is in NEW YORK, NY.
Recent filings by Buell Jennifer
- Oct 12, 2026: Open-market sale of INKT shares (Form 4, code S).
- Oct 11, 2026: Option exercise of INKT shares (Form 4, code M).
- Aug 5, 2026: Grant or award of AGEN derivative securities (Form 4, code A).
- Apr 24, 2026: Grants or awards of AGEN derivative securities (2 lines, Form 4, code A).
- Jan 2, 2026: Tax withholding of INKT shares (Form 4, code F).
Other insiders filing for MiNK Therapeutics, Inc. (INKT)
- WIINBERG ULF, Director
- Holcomb John Bradley, Director
- Behner Peter, Director
- Ryan Barbara, Director
- Corvese Brian, Director
- Orilall Melissa, Principal Financial Officer